Protocols · Cosmetic
Melanotan I dosage protocol
Dosage and protocol information sourced exclusively from PeptideDosages.com.
Read this first
Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.
Dosage protocol
PeptideDosages.com does not currently publish a matching protocol for Melanotan I. No dosage, schedule, reconstitution figure, or syringe-unit calculation is shown on this page.
Check the source protocol indexOther cosmetic compounds
Melanotan I: research background
What the compound is
Afamelanotide (also known as Melanotan I or Melanotan 1) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) (PMID 26315100). α-MSH is a hormone involved in the modulation of sebocyte, keratinocyte, and inflammatory cell activity (PMID 30859308).
How it is thought to work
Homogenous pigmentation can be induced by α-melanocyte-stimulating hormone (MSH) homologues (PMID 26315100). Afamelanotide's effects in certain conditions are associated with improving sunlight tolerance (PMID 30328490). It is also among a group of new approaches that have been developed as promising treatments for acne vulgaris (PMID 30859308).
Human evidence so far
Afamelanotide is a prescription drug for the orphan disease erythropoietic protoporphyria (EPP) (PMID 26315100). In patients with EPP and X-linked protoporphyria (XLP), afamelanotide is associated with better sunlight tolerance (human evidence) (PMID 30328490).
For vitiligo, afamelanotide is considered among several drugs being developed or reviewed for treatment, but there is currently no clearly outstanding or fully satisfactory treatment (human evidence) (PMID 38139134, PMID 40117616).
Case reports indicate that Melanotan I leads to the activation of dysplastic nevi (human evidence) (PMID 26315100).
Open questions and limitations
Structurally related α-MSH derivatives are available via the internet (PMID 26315100). Melanotan I and bleaching creams, which may contain mercury, are considered dangerous (PMID 26315100).
For vitiligo, long-term effectiveness and safety data for existing treatments, including afamelanotide, are still needed (PMID 38139134).
Key terms explained
Alpha-melanocyte-stimulating hormone (α-MSH): A hormone that can induce homogenous pigmentation (PMID 26315100).
Dysplastic nevi: A type of mole that can have atypical features and may be activated by Melanotan I (PMID 26315100).
Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Types of non-acute porphyrias where porphyrins accumulate in the skin and/or liver, causing photosensitivity (PMID 30328490).
Vitiligo: A common disorder characterized by depigmented macules and leukotrichia, resulting from the progressive destruction of melanocytes (PMID 40117616).
Studies cited in this section
- Vitiligo: Pathogenesis and New and Emerging Treatments. — International journal of molecular sciences, 2023 (PMID 38139134)
- Treatment Advances in Vitiligo: An Updated Review. — Dermatology practical & conceptual, 2025 (PMID 40117616)
- [Undesirable pigmentation]. — Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2015 (PMID 26315100)
- From pathogenesis of acne vulgaris to anti-acne agents. — Archives of dermatological research, 2019 (PMID 30859308)
- [Porphyrias-what is verified?]. — Der Internist, 2018 (PMID 30328490)
Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.
Nearby in the protocol A–Z
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.